Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AG-636

Small molecule · Inhibitor of dihydroorotate dehydrogenase (DHODH) · developed by Agios Pharmaceuticals

Phase 1 Most advanced trial (none active)
AGIO Developer
1 Registered trials

What is AG-636?

AG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme in de novo pyrimidine synthesis. It blocks UMP formation and DNA synthesis, inducing apoptosis in tumor cells. AG-636 is studied in lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
dihydroorotate dehydrogenase (DHODH)
Mechanism
Inhibitor of dihydroorotate dehydrogenase (DHODH)
Pathways
de novo pyrimidine synthesis, DNA synthesis, apoptosis
Therapy area
Oncology
Developer
Agios Pharmaceuticals, Inc. (AGIO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03834584 Phase 1 Lymphoma Terminated AGIO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lymphoma

More from Agios Pharmaceuticals

Mitapivat FDA approved AG-181 Phase 1 AG-236 Phase 2/3 AG-881 Phase 1 Tebapivat Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGIO page.

Follow AGIO, the company behind AG-636

See AGIO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGIO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.